Abstract: A fused ring compound shown in formula I or a pharmaceutically acceptable salt has a novel structure and good SOS1 inhibitory activity.

Abstract: A compound as represented by formula I or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing same, and the medical use thereof for preventing and/or treating HPK1-related diseases.

Abstract: A phenyldihydropyrimidine compound as represented by formula I, a tautomer or a pharmaceutically acceptable salt thereof. The phenyldihydropyrimidine compound has a good anti-HBV activity and can be used for preparing drugs for treating and/or preventing HBV infections.

Abstract: A human-machine dialogue system includes one or more processors configured to execute instructions to cause the human-machine dialogue system to perform operations. The operations include: performing intention clustering of a dialogue data sample based on a semantic representation of the dialogue data sample; constructing, based on a clustering result, a dialogue procedure corresponding to the dialogue data sample; obtaining a semantic representation corresponding to a voice dialogue of a user; performing intention analysis on the semantic representation to obtain an intention analysis result; determining, according to the intention analysis result and the dialogue procedure constructed in advance, a dialogue response; and performing voice interaction of the dialogue response with the user, wherein the dialogue response is an answer response to the voice dialogue, or a clarification response to clarify a dialogue intention of the voice dialogue.

Abstract: A heterocyclic compound, and a pharmaceutical composition thereof, a preparation method therefor, an intermediate thereof and an application thereof. The structure of the heterocyclic compound is as shown in formula (I) below. The compound has CDK7 inhibitory activity, and can be used to treat tumors and other diseases.

Abstract: Provided is a monocyclic ?-lactam compound as shown in general formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition containing the monocyclic ?-lactam compound as shown in general formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating bacterial infections.

Abstract: A compound with the structure of formula I or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug, or isotope label thereof: the KRAS G12C inhibitor compound has a good inhibitory effect on KRAS mutations, and can be used for the prevention and/or treatment of KRAS G12C-mediated diseases.

Abstract: Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.

Abstract: Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.

Abstract: The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.

Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

Abstract: The present application discloses novel 5-aminopyrazole carboxamide compounds as shown in formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. In addition, the present application further discloses a method for the preparation of the compounds, a pharmaceutical composition comprising a compound of the invention and the use of the compounds.

Abstract: Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

Abstract: Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.

Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.

Abstract: The present application discloses novel 5-aminopyrazole carboxamide compounds as shown in formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. In addition, the present application further discloses a method for the preparation of the compounds, a pharmaceutical composition comprising a compound of the invention and the use of the compounds.

Abstract: The present disclosure provides a composite substrate structure and a touch panel having composite substrate structure, for promoting abrasion resistance, visual transparency, and appearance. The composite substrate structure includes a transparent substrate and a diamond-like carbon layer. The diamond-like carbon layer is disposed on the transparent substrate and has a thickness less than or equal to about 15 nanometers.